In summary, our study demonstrated that Bru, a novel Akt1 inhibitor, effectively targeted Akt1 protein and suppressed its phosphorylation at Ser473 residues, which not only promoted mitochondria-mediated apoptosis via inhibiting the Akt1-phospho-Bad pathway in vitro and in vivo, but also impeded the ESCC cell’s metastasis via suppressing the Akt1 pathway in vitro. The gene discussed is BAD; the disease is esophageal squamous cell carcinoma.